Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 24, 2004 Alyce Lomax	J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain?
BusinessWeek April 17, 2006 Amy Barrett	Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool October 23, 2008 Brian Orelli	Boston Scientific Should Be Thankful The medical device maker's two-year-old acquisition of Guidant has saved it in the third quarter.
BusinessWeek August 8, 2005 Amy Barrett	BW 50: In A Bind Over Stents Safety concerns about drug-coated stents from Johnson & Johnson and Boston Scientific could open the way for rivals.
The Motley Fool February 1, 2005 Stephen D. Simpson	Stent Maker's Hearty Returns Medical device company Boston Scientific rebounds from cardiac stent recall with strong growth.
The Motley Fool July 26, 2004 W.D. Crotty	Boston Scientific on the Rebound The medical device maker posts robust earnings, softening the blow of the stent delivery system recall.
BusinessWeek September 22, 2003 Faith Arner	When Will This Stent See Circulation? Boston Scientific must clear the FDA, among other hurdles.
The Motley Fool October 25, 2007 Brian Orelli	Time to Invest in Stents? Stent devices have seen slumping sales over the last few years. Is it time now to invest in the companies that produce them?
The Motley Fool October 13, 2008 Brian Orelli	Too Little Too Late for Boston Scientific The company gets new stent approved, but it should have happened earlier.
The Motley Fool December 5, 2005 Stephen D. Simpson	Boston Scientific's Bold Move Acquiring Guidant would be risky, but it would give Boston Scientific exactly what it needs. It will be curious to see how J&J responds to this deal. Investors, take note.
The Motley Fool February 2, 2004 Alyce Lomax	Boston Scientific's Stent Hopes Nice quarter, but all eyes should be on the Taxus stent.
The Motley Fool May 27, 2004 Jeff Hwang	Guidant's Stent Stumble Yesterday, Guidant said that a regulatory filing for marketing approval of its Champion stainless steel stent could be delayed up to six months due to "issues" that may result in "manufacturing process modifications and/or stent design changes."
The Motley Fool July 19, 2005 Stephen D. Simpson	Waiting for Boston Scientific's Second Act The market for drug-coated stents is still lucrative, but BSX needs to deliver on its R&D efforts for long-term success. Investors, take note.
The Motley Fool May 28, 2009 Brian Orelli	Boston Scientific Back in an Atomic Way Can its tiny stent save the day?
The Motley Fool March 8, 2005 Stephen D. Simpson	The Stent Wars Continue Although Boston Scientific and Johnson & Johnson have been beating each other silly for market share, recent clinical data suggest little functional difference between drug-coated stents.
The Motley Fool July 19, 2004 W.D. Crotty	Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific?
The Motley Fool July 31, 2006 Stephen D. Simpson	Can Boston Scientific Get It Right? To boost investor confidence, management must first prove itself.
The Motley Fool May 14, 2008 Brian Orelli	Abbott Knocks Down Boston Scientific Abbott Labs proves its drug-eluting device works better than its competitors as it presented more data from its ongoing Spirit III trial.
The Motley Fool October 20, 2009 Robert Steyer	The Heart Company's Disheartening Forecast Boston Scientific scaled back its full-year forecast, and the market doesn't like it.
The Motley Fool September 26, 2005 Stephen D. Simpson	Boston Scientific: Finally Cheap Enough? Could shares of the medical device company now be attractive for long-term investors?
BusinessWeek October 29, 2007 Arlene Weintraub	Medtronic's Uncertain Endeavor The drug-coated stent might have made up for Medtronic's recent product recall, but renewed scrutiny of the device has executives scaling back expectations
The Motley Fool September 17, 2007 Brian Orelli	Can't See the Trees for the Forest Meta-analysis finds J&J's drug-coated stents are safer than Boston Scientific's stents, maybe. Can J&J use the complex study results to help their falling stent sales?
The Motley Fool January 29, 2009 Brian Orelli	No Buyer's Remorse at Boston Scientific The pacemakers and defibrillators that Guidant contributed to Boston Scientific's bottom line are still growing strong, but the company had to take a whopping $2.7 billion goodwill writedown because the value of what it purchased has changed.
The Motley Fool July 23, 2008 Brian Orelli	Leaner Boston Scientific Isn't Looking Healthy Investors are rightfully growing weary of Boston Scientific's ability to cut expenses on flat sales, and they send the stock down.
The Motley Fool March 22, 2004 Seth Jayson	Stent Wars Going Strong New studies show stents do little to stop heart attacks. What does that mean for stent makers?
The Motley Fool May 28, 2004 W.D. Crotty	Boston Scientific's Stent Gold Mine The company is starting two or more years of high profitability.
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool October 14, 2005 Stephen D. Simpson	Boston's Stunts With Stents Tough domestic stent competition is weighing on results from one-trick pony Boston Scientific. The company is in a transitional period and that's at least part of why the stock is down where it is.
The Motley Fool July 23, 2007 Ryan Fuhrmann	Boston Scientific Still Drowsy Facing continued top-line weakness, the medical device company may have to cut costs. Investors, take note.
The Motley Fool June 13, 2006 Jim Mueller	Foolish Investing and Boston Scientific In having bought Guidant, Boston Scientific might end up paying more than just the price. Investors, take note.
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
The Motley Fool December 13, 2006 Matthew Crews	Less Support for Drug-Eluting Stents? The FDA responds to a recent controversy. The regulator's stance represents a good-faith-take on the newer stents, which is good news for drug companies.
The Motley Fool June 29, 2006 Jim Mueller	Guidant, Devices, and Recalls, Oh My! To repair its acquisition's good name, Boston Scientific must quickly fix Guidant's problems. One analyst sees annual growth for Guidant's devices in the 10% to 15% range. No one knows how accurate that will prove to be, but it certainly provides hope for the troubled acquisition.
The Motley Fool November 9, 2009 Brian Orelli	Guidant: The Gift That Keeps on Giving And not in the good way. Last year, Boston Scientific took a whopping $2.7 billion goodwill writedown because it had to downgrade the value of what it got in acquiring Guidant.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Boston Scientific Regains Consciousness Recent Boston Scientific results show glimmers of hope. At current prices, the risk/reward tradeoff appears favorable enough to warrant a full checkup on the stock.
The Motley Fool June 22, 2005 Stephen D. Simpson	Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it.
The Motley Fool April 19, 2005 Stephen D. Simpson	Stent Success Propels Boston Scientific The medical device company's still ahead of the competition. Companies dependent upon one product line may be riskier than average, but there's no question that they can reap big-time profits when business is good.
The Motley Fool December 31, 2007 Brian Orelli	Boston Scientific Restarts Its Heart Boston Scientific receives European approval for its defibrillator, giving the company a revenue boost even if the U.S. approval is delayed.
The Motley Fool January 17, 2006 Stephen D. Simpson	High-Stakes Medical Device Chicken Boston Scientific has upped the ante again. Are they bluffing? Their latest offer is $80 a share -- $42 in cash and $38 in stock. Let's hope the board knows what it is doing, because it is staking the company on this.
The Motley Fool February 7, 2006 Stephen D. Simpson	Boston Scientific's Big Task The company won the battle for Guidant, but the hard work hasn't even begun. Value is value, and if Boston Scientific proves it can handle the considerable challenges ahead, this could ultimately be a very interesting stock again.
The Motley Fool January 12, 2007 Billy Fisher	Big Week at Boston Scientific The company's off to a great start so far for 2007. Investors, take note.
The Motley Fool May 27, 2010 Brian Orelli	Ever-Evolving Stent Technology (and How to Profit From It) Stay ahead of the curve.
The Motley Fool September 11, 2007 Billy Fisher	FDA Takes Issue With Boston Scientific Boston Scientific has until later this month to respond to an FDA letter prompted by the company's failure to disclose two of five deaths in a stent trial that the medical device maker abandoned in 2006. Investors take note.
The Motley Fool June 1, 2004 Jeff Hwang	Expanding Boston Scientific The medical device maker takes advantage of Taxus sales to expand.
The Motley Fool August 12, 2010 Brian Orelli	Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later.
The Motley Fool February 3, 2011 Brian Orelli	Add This Stock to Your Show-Me List Wait for the turnaround before investing in Boston Scientific; if it ever comes.
The Motley Fool February 5, 2008 Brian Orelli	Medtronic Endeavors to Compete The U.S. drug-eluting stent market just got a little more crowded, after Medtronic announces that the FDA had approved its Endeavor stent for marketing in the U.S.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
The Motley Fool April 8, 2005 Stephen D. Simpson	Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse?